News & Media
|Hemostemix Announces its Second US Patent|
|Apr 22 2014 -
Kyriat Weizmann, Israel
A Manufacturing Patent Covering the Manufacture of Endothelial Cells from Peripheral Blood
Hemostemix, Ltd. (“Hemostemix”, the “Company”) announced today the issuance of a patent from the United States Patent and Trademark Office (U.S. Patent No. 8,685,724) entitled “ In vitro techniques for use with stem cells”.
The patent pertains to the manufacture of the company’s therapeutic cell product from peripheral blood. The company’s lead product, manufactured using the methodologies disclosed in the patent, consists of a heterogenous mixture of cells, derived from peripheral blood collected by a simple blood draw.
The cells manufactured in accordance with the methodologies described in this newly issued patent meet specific product release criteria and constitute the foundation of the Company’s angiogenic (blood vessel growing) technology. The product developed on the basis of this technological platform will be used in a Phase 2 clinical trial for critical limb ischemia. The trial protocol was recently cleared by Health Canada and the trial is expected to commence mid-year.
This patent, the second issued by the USPTO, is part of a broad technology platform now protected by over 40 patents issued in major markets, such as the US, EU, Japan and China. The company continues to aggressively file and prosecute patents around all aspects of its technology as an important foundation for its global commercialization plans.
“The manufacturing processes which are the subject of this patent,” stated Hemostemix’ President, Dr. Valentin Fulga, “are an important pillar of our technology. This patent provides protection of the company’s manufacturing processes and further strengthens the company’s Intellectual Property in addition to the composition of matter patent that covers the actual cellular product, which was issued in the US in 2013.”
For more information, please contact firstname.lastname@example.org